FRONTEO AI Innovation Forum 2026 to Feature AI Drug Discovery Success Cases from Five Pharma Companies
FRONTEO will host the 'FRONTEO AI Innovation Forum 2026' on July 23, 2026. Five pharmaceutical companies, including Santen Pharmaceutical and Meiji Seika Pharma, will present results from implementing the AI drug discovery service, 'Drug Discovery AI Factory.'
📋 Article Processing Timeline
- 📰 Published: June 10, 2026 at 01:00
- 🔍 Collected: June 9, 2026 at 16:21
- 🤖 AI Analyzed: June 11, 2026 at 10:00 (41h 39m after Collected)
FRONTEO Inc. will host the 'FRONTEO AI Innovation Forum 2026' on July 23, 2026, at the Nihonbashi Life Science Hub in Tokyo. Five major pharmaceutical companies—NB Health Laboratory, Santen Pharmaceutical, Fuji Pharma, Maruishi Pharmaceutical, and Meiji Seika Pharma—will present practical results from using FRONTEO's AI drug discovery service, 'Drug Discovery AI Factory (DDAIF).'
The keynote address will be delivered by non-fiction author Susumu Shimoyama. This year's theme is 'The Frontline of Drug Discovery AI Factory Implementation—From Individual Projects to Business Alliances and Co-creation.' The forum will explore the latest trends as AI application expands from research labs to executive decision-making.
[Event Overview]
Date: July 23, 2026 (Thursday)
- Seminar: 15:00-18:00
- Networking: 18:00-19:30
Venue: Nihonbashi Life Science Hub (Hybrid on-site/online)
Capacity: Approx. 300 participants
[Program Overview]
- Opening: Masahiro Morimoto (CEO, FRONTEO)
- Keynote: Susumu Shimoyama
- Session 1: Santen Pharmaceutical (Takazumi Taniguchi)
- Session 2: Fuji Pharma (Takahiro Shimizu)
- Session 3: Meiji Seika Pharma (Junya Tsujii)
- Session 4: NB Health Laboratory (Yoshiyoshi Takayama)
- Session 5: Maruishi Pharmaceutical (Katsuto Inoue)
- Closing: Hiroyoshi Toyoshiba (CSO, FRONTEO)
FRONTEO remains committed to supporting innovative drug development and strengthening Japan’s drug discovery capabilities through its DDAIF and KIBIT solutions.
The keynote address will be delivered by non-fiction author Susumu Shimoyama. This year's theme is 'The Frontline of Drug Discovery AI Factory Implementation—From Individual Projects to Business Alliances and Co-creation.' The forum will explore the latest trends as AI application expands from research labs to executive decision-making.
[Event Overview]
Date: July 23, 2026 (Thursday)
- Seminar: 15:00-18:00
- Networking: 18:00-19:30
Venue: Nihonbashi Life Science Hub (Hybrid on-site/online)
Capacity: Approx. 300 participants
[Program Overview]
- Opening: Masahiro Morimoto (CEO, FRONTEO)
- Keynote: Susumu Shimoyama
- Session 1: Santen Pharmaceutical (Takazumi Taniguchi)
- Session 2: Fuji Pharma (Takahiro Shimizu)
- Session 3: Meiji Seika Pharma (Junya Tsujii)
- Session 4: NB Health Laboratory (Yoshiyoshi Takayama)
- Session 5: Maruishi Pharmaceutical (Katsuto Inoue)
- Closing: Hiroyoshi Toyoshiba (CSO, FRONTEO)
FRONTEO remains committed to supporting innovative drug development and strengthening Japan’s drug discovery capabilities through its DDAIF and KIBIT solutions.
FAQ
FRONTEO AI Innovation Forum 2026の開催日はいつですか？
2026年7月23日（木）です。セミナーは15:00から18:00、懇親会は18:00から19:30まで開催されます。
どの製薬企業が成果発表に登壇しますか？
エヌビィー健康研究所、参天製薬、富士製薬工業、丸石製薬、Meiji Seika ファルマの5社が登壇します。
今回のフォーラムのテーマは何ですか？
テーマは「Drug Discovery AI Factory実装最前線──プロジェクトから業務提携・共同創薬へと広がる共創の形」です。
FRONTEOが提供するAI創薬支援サービスは何と呼ばれますか？
「Drug Discovery AI Factory（DDAIF）」と呼ばれます。
参加申し込み方法を教えてください。
公式ウェブサイト（https://ai-forum.fronteo.com/）より事前登録が必要です。